Mucosal response of inactivated and recombinant COVID‐19 vaccines in Congolese individualsOriginal Article Published on 2023-12-272024-09-05 Journal: Immunity, Inflammation and Disease [Category] update2024, [키워드] antibody level IgG inactivated and recombinant COVID‐19 vaccines mucosal IgA‐mediated antibody [DOI] 10.1002/iid3.1116 PMC 바로가기 [Article Type] Original Article
Antibody Response to SARS-CoV-2 Vaccination in Patients with End-Stage Kidney Disease on HemodialysisArticle Published on 2023-12-012024-09-05 Journal: Vaccines [Category] update2024, [키워드] antibody level Chronic kidney disease COVID-19 vaccination [DOI] 10.3390/vaccines11121802 PMC 바로가기 [Article Type] Article
A comparative study of virus nucleic acid re-positive and non-re-positive patients infected with SARS-CoV-2 Delta variant strain in the Ningxia Hui Autonomous RegionArticle Published on 2022-12-132023-07-11 Journal: Frontiers in Public Health [Category] COVID19(2023년), [키워드] antibody level COVID-19 vaccine Delta variant infection virus nucleic acid CT value virus nucleic acid re-positive. [DOI] 10.3389/fpubh.2022.1023797 PMC 바로가기
Immunological responses following the third dose of the BNT162b2 SARS-CoV-2 vaccine among Japanese healthcare workersArticle Published on 2022-11-012022-11-15 Journal: Journal of infection and chemotherapy : official j [Category] COVID19(2023년), SARS, 진단, [키워드] age alcohol all age groups anti-RBD antibody antibody level antibody levels Antibody Response Antibody titer Asian baseline binding domain BNT162b2 BNT162b2 mRNA BNT162b2 vaccine Boosted vaccination booster dose booster vaccination conducted COVID-19 COVID-19 vaccine dose eight elevated Ethnic groups group healthcare worker Healthcare workers healthy IgG information investigated Japan Japanese median median titer of BNT162b2 participant Prevent provided RBD response SARS-CoV-2 vaccine second dose serum shown significant increase the vaccine university vaccination Welfare [DOI] 10.1016/j.jiac.2022.07.006 PMC 바로가기
Sustained seropositivity up to 20.5 months after COVID-19Article Published on 2022-10-132022-11-15 Journal: BMC Medicine [Category] COVID19(2023년), SARS, 변종, 진단, 치료기술, [키워드] absence addition affecting age anosmia/hypogeusia Anti-spike antibodies antibody antibody level Barcelona Beta chest pain circulating Cohort Comorbidity comparable COVID-19 cutaneous symptom Delta Duration duration of symptoms evaluated Factor faster Fever FIVE Frequency Gamma headache Health care Health care worker health care workers Hospitalization Humoral immunity hypertension IgA IgA response IgG IgM Infection initial Kinetics long-lasting multivariable regression models nucleocapsid antigen obesity onset of symptom oxygen supply pandemic participant persistence predominant protective role Reinfection remained responders response SARS-CoV-2 SARS-CoV-2 antigen SARS-CoV-2 spike Seroprevalence smoking Spain STABLE study period subset sustained Tachycardia vaccination variant variants of concern Wuhan [DOI] 10.1186/s12916-022-02570-3 PMC 바로가기
Humoral immunogenicity of COVID-19 vaccines in patients with inflammatory rheumatic diseases under treatment with Rituximab: a case-control study (COVID-19VacRTX)Article Published on 2022-10-062022-11-15 Journal: Rheumatology (Oxford, England) [Category] COVID19(2023년), SARS, 진단, 치료기술, [키워드] Ad26.COV2.S ANCA-associated vasculitis anti-CD20 antibody antibody level Antibody titre approved AZD1222 B cell B-cell B-cells blood sample case-control study CD19+ COVID-19 COVID-19 vaccine dose ELISA evaluated examined Factor first vaccination Frame help humoral humoral immune response immunogenicity Immunoglobulin Improved increased risk Inflammatory International mAb Moderna outcomes parameter Patient quantified RA reduced regimen rheumatic disease rituximab RNA-1273 RTX SARS-CoV-2 severe COVID-19 synchronization the patient therapeutic therapy treated Treatment Univariate analysis vaccination Vaccine [DOI] 10.1093/rheumatology/keac036 PMC 바로가기
The persistence of anti-Spike antibodies following two SARS-CoV-2 vaccine doses in patients on immunosuppressive therapy compared to healthy controls-a prospective cohort studyArticle Published on 2022-10-052022-11-15 Journal: BMC Medicine [Category] COVID19(2023년), SARS, 진단, [키워드] 95% CI analyzed anti-RBD antibodies binding antibody antibody level blood sample bowel collected combination treatment Control controls COVID-19 declined defined disease dose enrolled Factor greater healthy healthy control healthy individuals Humoral immunity identify Immune-mediated inflammatory disease immunosuppressive Immunosuppressive medication Inflammatory bowel disease inhibitor initial interval median Multivariable regression Necrosis participant Patient patients persistence prospective cohort study Protein provided psoriatic arthritis RBD reduction reduction in Rheumatic diseases rheumatoid arthritis SARS-CoV-2 SARS-CoV-2 vaccination SARS-CoV-2 vaccine serologic Serologic response spike spondyloarthritis Support the receptor-binding domain the SARS-CoV-2 Therapies therapy ulcerative colitis vaccination vaccine dose [DOI] 10.1186/s12916-022-02587-8 PMC 바로가기
Comparison of antibody response durability of mRNA-1273, BNT162b2, and Ad26.COV2.S SARS-CoV-2 vaccines in healthcare workersArticle Published on 2022-10-012022-11-15 Journal: International Journal of Infectious Diseases [Category] COVID19(2023년), SARS, 진단, [키워드] Ad26.COV2.S Administered age analysis of variance Anti-spike anti-spike antibody antibody level Antibody Response Antibody responses blood draws BNT162b2 BNT162b2 vaccine booster dose COVID-19 COVID-19 infection COVID-19 vaccination COVID-19 vaccinations Effectiveness enzyme-linked immunosorbent female group healthcare worker Immunosuppression interquartile range IQR Linear regression median mRNA-1273 mRNA-1273 vaccine neutralizing antibody outcome participant Participants Primary outcome SARS-CoV-2 SARS-CoV-2 vaccine significantly significantly higher vaccination Vaccine vaccine effectiveness variable [DOI] 10.1016/j.ijid.2022.08.022 PMC 바로가기
Antibody response three months after SARS-CoV-2 infectionSARS-CoV-2 감염 3개월 후 항체 반응Article Published on 2022-10-012022-09-12 Journal: Journal of medical virology [Category] COVID19(2023년), MERS, SARS, 진단, [키워드] acute respiratory syndrome anti-SARS-CoV-2 antibody antibody level Antigen applied coated with collected coronavirus Coronavirus disease-19 cough COVID-19 COVID-19 infection determine ELISA fatigue Hospitalized IgG immune immune responses Immunoglobulin individual individuals Infection Insomnia joint loss of taste Pain pandemic positive Postinfection Prevent problem public health Reinfection Research SARS Coronavirus SARS-CoV-2 SARS-CoV-2 antibodies SARS-COV-2 infection serum antibody serum sample state Symptom Tarsus tested those with comorbidities threshold virus virus classification weakness [DOI] 10.1002/jmv.27909 PMC 바로가기 [Article Type] Article
SARS-CoV-2 spike IgG titres up to 137 days following Comirnaty mRNA COVID-19 vaccination, Israel, February to May 2021Article Published on 2022-10-012022-11-15 Journal: Eurosurveillance [Category] COVID19(2023년), SARS, 진단, [키워드] antibody antibody level baseline characteristics body mass cardiovascular disease Chronic kidney disease chronic obstructive Comorbidity Concentration conducted congestive heart failure coronavirus COVID-19 COVID-19 vaccination COVID-19 vaccine cut-off diabete dose Factor female first dose geometric mean GFR glomerular filtration rate GMC GMCs IgG IgG antibodies IgG antibody Immunosuppression Infection Inflammatory bowel disease levels of antibody male mRNA Patient peaked pulmonary disease remained repeated reported resource retrospective cohort study SARS-CoV-2 SARS-CoV-2 spike serological serology solid malignancy the antibody the SARS-CoV-2 titre vaccination were used [DOI] 10.2807/1560-7917.ES.2022.27.40.2100703 PMC 바로가기